SYDNEY, Thursday 02 March 2017

Cellmid Limited (ASX: CDY) is pleased to advise that a manuscript describing the screening approach and clinical study carried out by Cellmid’s wholly owned subsidiary, Advangen Limited, has been published in the journal Clinical, Cosmetic, and Investigational Dermatology 10: 71-85. 27 Feb 2017. 

The paper, titled “Promotion of Anagen, increased Hair Density and Reduction of Hair Fall in a Clinical Setting Following Identification of FGF5 Inhibiting Compounds via a Novel Two Stage Process”, describes the development and screening programme behind the Company’s FGF5 inhibitory technology and the discovery of novel, single molecule FGF5 inhibitors.

Click here to